Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate to severe non-malignant pain and opioid induced constipation: a UK cost-utility analysis

William Dunlop; Reiner Uhl; Iftekhar Khan; Anna Taylor; Garry Barton

doi:10.3111/13696998.2012.665279

Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate to severe non-malignant pain and opioid induced constipation: a UK cost-utility analysis

William Dunlop, Reiner Uhl, Iftekhar Khan, Anna Taylor, Garry Barton

Research output: Contribution to journal › Article › peer-review

46 Citations (Scopus)

Abstract

Objective:
To compare the cost effectiveness of prolonged release oxycodone/naloxone (OXN) tablets (Targinact) and prolonged release oxycodone (OXY) tablets (OxyContin) in patients with moderate-to-severe non-malignant pain and opioid-induced constipation (OIC) from the perspective of the UK healthcare system.

Original language	English
Pages (from-to)	564-575
Number of pages	12
Journal	Journal of Medical Economics
Volume	15
DOIs	https://doi.org/10.3111/13696998.2012.665279
Publication status	Published - 2012

Access to Document

10.3111/13696998.2012.665279

Cite this

Dunlop, W., Uhl, R., Khan, I., Taylor, A., & Barton, G. (2012). Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate to severe non-malignant pain and opioid induced constipation: a UK cost-utility analysis. Journal of Medical Economics, 15, 564-575. https://doi.org/10.3111/13696998.2012.665279

@article{5bbe4ebed1264cab973ec60dc6ea1468,

title = "Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate to severe non-malignant pain and opioid induced constipation: a UK cost-utility analysis",

abstract = "Objective: To compare the cost effectiveness of prolonged release oxycodone/naloxone (OXN) tablets (Targinact) and prolonged release oxycodone (OXY) tablets (OxyContin) in patients with moderate-to-severe non-malignant pain and opioid-induced constipation (OIC) from the perspective of the UK healthcare system.",

author = "William Dunlop and Reiner Uhl and Iftekhar Khan and Anna Taylor and Garry Barton",

year = "2012",

doi = "10.3111/13696998.2012.665279",

language = "English",

volume = "15",

pages = "564--575",

journal = "Journal of Medical Economics",

issn = "1941-837X",

publisher = "Informa Healthcare",

}

Dunlop, W, Uhl, R, Khan, I, Taylor, A & Barton, G 2012, 'Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate to severe non-malignant pain and opioid induced constipation: a UK cost-utility analysis', Journal of Medical Economics, vol. 15, pp. 564-575. https://doi.org/10.3111/13696998.2012.665279

Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate to severe non-malignant pain and opioid induced constipation: a UK cost-utility analysis. / Dunlop, William; Uhl, Reiner; Khan, Iftekhar et al.
In: Journal of Medical Economics, Vol. 15, 2012, p. 564-575.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate to severe non-malignant pain and opioid induced constipation: a UK cost-utility analysis

AU - Dunlop, William

AU - Uhl, Reiner

AU - Khan, Iftekhar

AU - Taylor, Anna

AU - Barton, Garry

PY - 2012

Y1 - 2012

N2 - Objective: To compare the cost effectiveness of prolonged release oxycodone/naloxone (OXN) tablets (Targinact) and prolonged release oxycodone (OXY) tablets (OxyContin) in patients with moderate-to-severe non-malignant pain and opioid-induced constipation (OIC) from the perspective of the UK healthcare system.

AB - Objective: To compare the cost effectiveness of prolonged release oxycodone/naloxone (OXN) tablets (Targinact) and prolonged release oxycodone (OXY) tablets (OxyContin) in patients with moderate-to-severe non-malignant pain and opioid-induced constipation (OIC) from the perspective of the UK healthcare system.

U2 - 10.3111/13696998.2012.665279

DO - 10.3111/13696998.2012.665279

M3 - Article

SN - 1941-837X

VL - 15

SP - 564

EP - 575

JO - Journal of Medical Economics

JF - Journal of Medical Economics

ER -